[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100370740":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":30,"centralContacts":34,"locations":42,"responsibleParty":61,"collaborators":10,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":10,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":10,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Neurocognitive evaluation prior to and following CART",null,[12,13,14],"Behavioral: neurocognitive evaluations","Diagnostic Test: brain MRIs","Other: Blood samples",[16,21,26],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"BEHAVIORAL","neurocognitive evaluations","The test battery consists of validated and reliable measures of attention, executive functions and memory.",[9],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"DIAGNOSTIC_TEST","brain MRIs","Patients will undergo baseline and follow-up research MRIs in the same scanner at MSKCC (3 Tesla scanner (GE, Discovery 750W, USA) with a GEM HNU 24-channel head coil) (total scan duration=15 minutes).",[9],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"Blood samples","Research blood samples will be collected pre-CAR T infusion; day of CART infusion (day 0), and post-infusion days 7, 14, 21, 28 (+\u002F- 7 days), at start of neurotoxicity, and at 3-4 months and 6-7 months post-CART.",[9],[31],{"name":32,"affiliation":5,"role":33},"Bianca Santomasso, MD, PhD","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":10,"email":38},"CONTACT","646-888-2092","santomab@mskcc.org",{"name":40,"role":36,"phone":41,"phoneExt":10,"email":10},"Denise Correa, PhD","212-610-0487",[43],{"facility":5,"status":44,"city":45,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","New York","10065","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-74.00597,40.71427,{"lat":53,"lon":52},[56,57,59],{"name":32,"role":36,"phone":37,"phoneExt":10,"email":10},{"name":58,"role":36,"phone":41,"phoneExt":10,"email":10},"Dennis Correa, PhD",{"name":60,"role":33,"phone":10,"phoneExt":10,"email":10},"Bianca Santomasso, MD",{"type":62,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100370740","looking-at-cognitive-and-brain-changes-in-people-with-lymphoma-receiving-car-t-therapy-100370740",false,"NCT04107285","Looking at Cognitive and Brain Changes in People With Lymphoma Receiving CAR-T Therapy","A Study of Longitudinal Neurocognitive and Neuroimaging Evaluations for Adult Patients With Lymphoma Receiving CD19 CAR T Cell Therapy","Inclusion Criteria:\n\n* Patients must be 18 years of age or older\n* Planned treatment with commercial CD19-specific CAR T cells (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, or brexacabtagene autoleucel) for lymphoma.\n* Patients must have adequate end organ function for CAR T cell therapy\n\n  * Eastern Cooperative Group (ECOG) performance status of 0 to 2\n  * Meet cardiac, pulmonary, hematologic, hepatic, and renal requirements for CART therapy as described in corresponding product package insert\n* No evidence of central nervous system disease at study entry\n* Fluent and able to communicate well enough in English to complete the study assessments and provide informed consent, in the judgment of the consenting professional. o Patients who report that English is not their primary language will be asked the US Census English proficiency question: \"How well do you speak English,\" and the answer \"very well\" will be required\n\nExclusion Criteria:\n\n* Signs and\u002For symptoms of central nervous system cancer (e.g., metastases, leptomeningeal disease) as determined by their physician, medical records, or by a brain MRI, either at the time of enrollment or during the study period.\n* Current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient report\n* History of neurodegenerative disease, or traumatic brain injury with loss of consciousness (\\>60 minutes), as per medical records or patient report\n* A history of epilepsy as per medical records or patient report\n* Current ongoing substance abuse and\u002For history of substance abuse, as per medical records or patient report\n* Evidence of visual or auditory impairment that would preclude completion of the assessments, as per medical records or patient report\n* Contraindications to MRI examinations as per standard screening guidelines used in the Department of Radiology (i.e., ferromagnetic material or implants, pacemakers or defibrillators, stents, claustrophobia)","ALL","18 Years",{"count":73,"type":74},120,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to learn about possible changes in cognitive (mental) abilities, such as memory skills and concentration, and in brain anatomy (structure) and function, in people with lymphoma receiving CAR-T therapy.",[78],"Lymphoma Receiving CAR-T Therapy",[80,81,82],"Neurocognitive Evaluations","Neuroimaging Evaluations","19-268","2025-10-23",{"date":85,"type":86},"2025-10-24","ACTUAL",{"date":88,"type":86},"2019-09-25",{"date":90,"type":74},"2026-09",{"name":5,"class":6},1]